{"type":"trials","record":{"id":41486,"source_id":"clinicaltrials-gov","external_id":"NCT07660640","title":"Long-Term Follow Up of VOY-101 Non-nAMD Extension Study","brief_summary":"Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration","overall_status":"Enrolling By Invitation","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Perceive Biotherapeutics, Inc.","enrollment":88,"countries":["United States","Israel"],"start_date":"2026-03-03","completion_date":"2031-08-30","last_update_date":"2026-06-22","source_url":"https://clinicaltrials.gov/study/NCT07660640","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Enrolling By Invitation. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"OASIS","age_range":"50 Years","comparator":null,"organization":"Perceive Biotherapeutics, Inc.","interventions":["observational study","VOY-101"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Frequency of ocular and systemic VOY-101 related AEs — 3 years"],"design_description":null,"source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration (AMD)","Non-Neovascular Age-Related Macular Degeneration","observational study","VOY-101"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07660640","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-03-03 to 2031-08-30","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.821Z","intervention":["observational study","VOY-101"],"participants":88,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Frequency of ocular and systemic VOY-101 related AEs — 3 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41486","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}